Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges

Science Communicator Platform

Share By

Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges Publisher

Yang P ; Khoshandam M ; Bhia I ; Raji S ; Soltaninejad H ; Hosseinkhani S ; Sani M ; Hamidieh AA ; Sheykhhasan M

Source: Asian Journal of Pharmaceutical Sciences Published:2025

Abstract

CRISPR represent a groundbreaking genome-editing technology that has revolutionized genetic modification. This innovative tool offers an unparalleled revolution in the future treatment of genetic disorders, neurological diseases, infectious diseases and cancer. Despite the rapid expansion of CRISPR applications, its clinical use in humans is still relatively limited, with only 69 active clinical trials and 6 completed studies reported so far. This review examined current clinical trials and their processes in addressing various diseases via the CRISPR/Cas system. While earlier literatures have focused mainly on delivery methods and materials for CRISPR/Cas9, our review emphasized innovative targeting conditions and approaches for novel and functional therapeutic designs. In addition, we reviewed recent research to increase the efficiency of CRISPR editing in the management of genetic disorders and cancer, while exploring their future challenges and potential. This review provided a unique perspective on the advancement of CRISPR technology. By addressing these aspects, we aim to contribute to ongoing efforts to improve CRISPR-based therapies and expand their clinical applications, ultimately striving to transform the future of medical treatment. © 2025 Shenyang Pharmaceutical University.

Related Docs

View other Related Docs

1. Crispr Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential, Cell Proliferation (2025)

2. Clinical Applications of the Crispr/Cas9 Genome-Editing System: Delivery Options and Challenges in Precision Medicine, Genes and Diseases (2024)

3. Smart Strategies for Precise Delivery of Crispr/Cas9 in Genome Editing, ACS Applied Bio Materials (2022)

Experts (# of related papers)

View all Related Experts

Amir Ali Hamidieh (2)

Zohreh Saltanatpouri (1)

Other Related Docs

4. Crispr-Cas9 in Leukemia Immunotherapy: Precision Engineering of Car-T Cells and Tumor-Microenvironment Modulation, Molecular Biology Reports (2026)

5. Harnessing Nanoparticles for the Efficient Delivery of the Crispr/Cas9 System, Nano Today (2020)

6. The Trend of Crispr-Based Technologies in Covid-19 Disease: Beyond Genome Editing, Molecular Biotechnology (2023)

7. Crispr-Cas9 in Basic and Translational Aspects of Cancer Therapy, BioImpacts (2024)

8. The Crispr Growth Spurt: From Bench to Clinic on Versatile Small Rnas, Journal of Microbiology and Biotechnology (2017)

9. Smart Arginine-Equipped Polycationic Nanoparticles for P/Crispr Delivery Into Cells, Nanotechnology (2022)

10. Exploring Advanced Crispr Delivery Technologies for Therapeutic Genome Editing, Small Science (2024)

11. Nanoparticles-Mediated Crispr/Cas9 Delivery: Recent Advances in Cancer Treatment, Journal of Drug Delivery Science and Technology (2020)

12. The Impact of Crispr-Cas System on Antiviral Therapy, Advanced Pharmaceutical Bulletin (2018)

13. Crispr-Based Gene Editing in Plants: Focus on Reagents and Their Delivery Tools, BioImpacts (2025)

14. Therapeutic Applications of Crispr/Cas9 System in Gene Therapy, Biotechnology Letters (2018)

15. Crispr/Cas and Artificial Intelligence to Improve Precision Medicine: Future Perspectives and Potential Limitations, Human Gene (2024)

16. Genetic Modification of Cystic Fibrosis With Δf508 Mutation of Cftr Gene Using the Crispr System in Peripheral Blood Mononuclear Cells, Iranian Journal of Basic Medical Sciences (2020)

17. Hpv-Driven Cancers: A Looming Threat and the Potential of Crispr/Cas9 for Targeted Therapy, Virology Journal (2025)

18. Mxenes for Crispr-Based Diagnostics: Innovations and Advancements, Microchemical Journal (2025)

19. Prime Editing: The State-Of-The-Art of Genome Editing, Meta Gene (2020)

20. Pipeline for the Generation of Gene Knockout Mice Using Dual Sgrna Crispr/Cas9-Mediated Gene Editing, Analytical Biochemistry (2019)

Style	Citing Format
MLA	Yang P, et al.. "Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges." Asian Journal of Pharmaceutical Sciences, vol. 20, no. 6, 2025, pp. -.
APA	Yang P, Khoshandam M, Bhia I, Raji S, Soltaninejad H, Hosseinkhani S, Sani M, Hamidieh AA, Sheykhhasan M (2025). Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges. Asian Journal of Pharmaceutical Sciences, 20(6), -.
Chicago	Yang P, Khoshandam M, Bhia I, Raji S, Soltaninejad H, Hosseinkhani S, Sani M, Hamidieh AA, Sheykhhasan M. "Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges." Asian Journal of Pharmaceutical Sciences 20, no. 6 (2025): -.
Harvard	Yang P et al. (2025) 'Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges', Asian Journal of Pharmaceutical Sciences, 20(6), pp. -.
Vancouver	Yang P, Khoshandam M, Bhia I, Raji S, Soltaninejad H, Hosseinkhani S, et al.. Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges. Asian Journal of Pharmaceutical Sciences. 2025;20(6):-.
BibTex	@article{ author = {Yang P and Khoshandam M and Bhia I and Raji S and Soltaninejad H and Hosseinkhani S and Sani M and Hamidieh AA and Sheykhhasan M}, title = {Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges}, journal = {Asian Journal of Pharmaceutical Sciences}, volume = {20}, number = {6}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Yang P AU - Khoshandam M AU - Bhia I AU - Raji S AU - Soltaninejad H AU - Hosseinkhani S AU - Sani M AU - Hamidieh AA AU - Sheykhhasan M TI - Integrating Crispr/Cas Technology With Clinical Trials: Principles, Progress and Challenges JO - Asian Journal of Pharmaceutical Sciences VL - 20 IS - 6 SP - EP - PY - 2025 ER -

Science Communicator Platform

Authors

Abstract